ICVB-1042

AXP000055.1 · Oncolytic virus

Platform
adenovirus (Ad5, CD46-binding, E2F-dependent replication)
Originator
IconOVir Bio
Sponsor
IconOVir Bio

Names

NameTypeSource
ICVB-1042preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (ICVB-1042)
Replication
conditionally replicating
Modifications
E2F-dependent replication; CD46-binding capsid
Transgenes
YPet reporter protein
Route
intratumoral, intravenous
Source
evidence

Cross-references

NCI Thesaurus
C200413

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05904236Safety and Tolerability of Intravenous Administration of ICVB-1042TerminatedPhase 12023-06-012024-12-1117Patients With Advanced Solid Tumors

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39271928Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment.Communications biology2024cited by trial NCT05904236

Notes

First patient dosed July 2023 in phase 1 NCT05904236; given intratumorally and intravenously in advanced solid tumours. Carries a YPet reporter per NCIt.

How to cite

ICVB-1042 (AXP000055.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000055.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.